| answer text |
<p>The United Kingdom has a long-established and globally-recognised track record
of assessing the price of new, innovative medicines by their clinical benefit and
value, rather than by their development costs or international reference prices.</p><p>The
UK will engage constructively with the talks at the World Health Assembly to achieve
the best outcome for people here and globally, including in low and middle income
countries. Pricing arrangements are the responsibility of Member States and are highly
context specific, but the Department supports information sharing and mutual learning
initiatives, where appropriate, in seeking to improve value for money for country
procurement budgets.</p>
|
 |
